Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Considering buying CVX stock? Here’s what analysts think: Read This Next: Photo via Shutterstock ...

The Lovesac Company (NASDAQ:LOVE) will release earnings results for the third quarter before the opening bell on Thursday, Dec. 11.Analysts expect the Stamford, Connecticut-based company to report quarterly loss at 46 cents per share, versus a year-ago loss of 1 cent per share. The consensus estimate for Lovesac's quarterly revenue is $154.17 million. Last year, it reported $149.91 million in revenue, according to Benzinga Pro.On Nov. 20, Lovesac named Wan Ling Martello to its board of directors.Shares of L ...

Core Insights - Macy's, Inc. is expected to report a quarterly loss of 13 cents per share for Q3, a decline from a profit of 4 cents per share in the same period last year [1] - The consensus estimate for Macy's quarterly revenue is $4.56 billion, down from $4.74 billion a year earlier [1] - The company's board declared a regular quarterly dividend of 18.24 cents per share on October 24 [1] Stock Performance - Shares of Macy's fell 0.5% to close at $22.71 [2] Analyst Ratings - UBS analyst Jay Sole maintained a Sell rating and raised the price target from $6.5 to $7 [4] - Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating and increased the price target from $17 to $22 [4] - Citigroup analyst Paul Lejuez maintained a Neutral rating and raised the price target from $16 to $19 [4] - BTIG analyst Robert Drbul initiated coverage with a Neutral rating [4] - Morgan Stanley analyst Alex Straton maintained an Equal-Weight rating and raised the price target from $12 to $16 [4]

Pfizer Inc. (NYSE:PFE) will release earnings results for the third quarter before the opening bell on Tuesday, Nov. 4.Analysts expect the health care company to report quarterly earnings at 64 cents per share, down from $1.06 per share in the year-ago period. The consensus estimate for Pfizer’s quarterly revenue is $16.52 billion, down from $17.7 billion a year earlier, according to Benzinga Pro.On Friday, Pfizer filed a lawsuit against Metsera, Inc. (NASDAQ:MTSR), its Board of Directors, and Novo Nordisk ( ...

Core Insights - Top Wall Street analysts have revised their outlook on several prominent companies, indicating a shift in market sentiment and potential investment opportunities [1] Company Analysis - Analysts are considering buying DPZ stock, suggesting a positive outlook for the company [1]

Group 1: Company Performance and Analyst Ratings - Rubrik, Inc. reported second-quarter revenue of $309.86 million, a 51% year-over-year increase, surpassing the consensus estimate of $282.22 million, and had a loss of three cents per share, better than the expected loss of 34 cents per share [1] - Seagate Technology Holdings plc received an Outperform rating from Bernstein analyst Mark Newman with a price target of $250, but caution is advised due to its recent price run [2] - Cleveland-Cliffs Inc. was maintained with an Equal-Weight rating by Wells Fargo, with a price target raised from $10 to $11, while BofA Securities maintained a Neutral rating and increased the price target from $9.5 to $12.5 [3] - SAP SE was noted as a buy following a good quarter and the announcement of a revamped strategy for digital sovereignty and AI innovation, expanding its SAP Sovereign Cloud portfolio [4] Group 2: Stock Price Movements - Seagate shares increased by 1.1% to $213.36 [7] - Rubrik shares decreased by 1.5% to close at $73.89 [7] - Eagle Materials shares fell by 1.7% to settle at $230.02 [7] - Cleveland-Cliffs shares dropped by 3.7% to $11.29 [7] - SAP shares rose by 3.1% to close at $261.42 [7]

Group 1 - The company forecasted slower growth in the second half of the year, leading to a 7.5% decline in its stock price to $120.74 despite better-than-expected second-quarter results [1] - Following the forecast, five analysts raised their price targets, with J.P. Morgan Securities increasing its target from $120 to $130, while three analysts reduced their targets [1] - The 12-month consensus price target for the company is now $140.85, representing a 15.9% premium to current stock levels [2] Group 2 - The company's stock is currently trading at its lowest level since early May, down 7.5% year-to-date, and is below all daily moving averages between the 20- and 320-day trendlines [2] - Options trading activity for the company is significantly high, with 26,000 calls and 30,000 puts exchanged, indicating increased interest in the stock [3] - The most popular options include the weekly 8/8 125-strike put and the 117-strike put in the same series [3]

Core Viewpoint - Ollie's Bargain Outlet is set to release its first-quarter earnings results, with expectations of a slight decline in earnings per share and an increase in revenue compared to the previous year [1]. Financial Performance - The company is projected to report quarterly earnings at 71 cents per share, down from 73 cents per share in the same period last year [1]. - Quarterly revenue is expected to reach $565.75 million, an increase from $508.82 million a year earlier [1]. - In the fourth quarter, adjusted earnings per share were reported at $1.19, aligning with analyst consensus, while quarterly sales were $667.1 million, which was a 2.8% year-over-year increase but fell short of the consensus estimate of $674.5 million [2]. Analyst Ratings and Price Targets - Keybanc analyst Bradley Thomas maintained an Overweight rating and increased the price target from $125 to $135 [9]. - JP Morgan analyst Matthew Boss also maintained an Overweight rating, raising the price target from $135 to $137 [9]. - Piper Sandler analyst Peter Keith maintained an Overweight rating but reduced the price target from $126 to $124 [9]. - UBS analyst Mark Carden maintained a Neutral rating and raised the price target from $117 to $123 [9]. - Morgan Stanley analyst Simeon Gutman maintained an Equal-Weight rating and increased the price target from $108 to $118 [9].